Hostname: page-component-8448b6f56d-tj2md Total loading time: 0 Render date: 2024-04-19T22:38:48.395Z Has data issue: false hasContentIssue false
  • English
  • Français

National survey study of nirmatrelvir-ritonavir prescribing processes and access barriers during the severe acute respiratory coronavirus virus 2 (SARS-CoV-2) omicron surge of the coronavirus disease 2019 (COVID-19) pandemic

Published online by Cambridge University Press:  20 April 2023

Rebecca Wang Open the ORCID record for Rebecca Wang [Opens in a new window] ,
Michael S. Calderwood ,
Craig P. Worby ,
Jose R. Mercado  and
Justin J. Kim Open the ORCID record for Justin J. Kim [Opens in a new window]
Rebecca Wang*
Affiliation:
Section of Infectious Diseases and International Health, Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire
Michael S. Calderwood
Affiliation:
Section of Infectious Diseases and International Health, Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire
Craig P. Worby
Affiliation:
Department of Pharmacy, Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire
Jose R. Mercado
Affiliation:
Section of Hospital Medicine, Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire
Justin J. Kim
Affiliation:
Section of Infectious Diseases and International Health, Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire
*
Author for correspondence: Rebecca Wang, E-mail: rebecca.wang@hitchcock.org
Get access Rights & Permissions [Opens in a new window]

Abstract

In this national survey, we found that individual patient assessments by pharmacists were more common at facilities using centralized prescribing for nirmetralvir-ritonavir (Paxlovid) than decentralized prescribing. Provider discomfort was initially less with centralized prescribing, but later, there was no difference in provider discomfort based on prescribing mechanism.

Type
Concise Communication
Information
Infection Control & Hospital Epidemiology , Volume 44 , Issue 11 , November 2023 , pp. 1881 - 1883
Check for updates
Copyright
© The Author(s), 2023. Published by Cambridge University Press on behalf of The Society for Healthcare Epidemiology of America

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Hammond, J, Leister-Tebbe, H, Gardner, A, et al. Oral nirmatrelvir for high-risk, nonhospitalized adults with COVID-19. N Engl J Med 2022;386:1397–1408.10.1056/NEJMoa2118542CrossRefGoogle Scholar
Ganatra, S, Dani, SS, Ahmad, J, et al. Oral nirmatrelvir and ritonavir in non-hospitalized vaccinated patients with COVID-19. Clin Infect Dis 2023;76:563–572.10.1093/cid/ciac673CrossRefGoogle Scholar
Dryden-Peterson, S, Kim, A, Kim, AY, et al. Nirmatrelvir plus ritonavir for early COVID-19 in a large US health system: a population-based cohort study. Ann Intern Med 2023;176:77–84.10.7326/M22-2141CrossRefGoogle Scholar
Najjar-Debbiny, R, Gronich, N, Weber, G, et al. Effectiveness of paxlovid in reducing severe COVID-19 and mortality in high-risk patients. Clin Infect Dis 2023;76:e342–e349.10.1093/cid/ciac443CrossRefGoogle ScholarPubMed
Lewnard, JA, Malden, D, Hong, V, et al. Effectiveness of nirmatrelvir-ritonavir against hospital admission: a matched cohort study in a large US healthcare system. medRxiv 2023. doi: 10.02.22280623.CrossRefGoogle Scholar
Bariola, JR, McCreary, EK, Khadem, T, et al. Establishing a distribution network for COVID-19 monoclonal antibody therapy across a large health system during a global pandemic. Open Forum Infect Dis 2021;8:ofab151.10.1093/ofid/ofab151CrossRefGoogle Scholar
Drug–drug interactions between ritonavir-boosted nirmatrelvir (paxlovid) and concomitant medications. National Institutes of Health website. https://www.covid19treatmentguidelines.nih.gov/therapies/antivirals-including-antibody-products/ritonavir-boosted-nirmatrelvir--paxlovid-/paxlovid-drug-drug-interactions/. Published 2022. Accessed December 10, 2022.Google Scholar
Abramowitz, PW, Thompson, KK, Cobaugh, DJ. Pharmacists: essential providers of COVID-19 care. Am J Health Syst Pharm 2022;79:927–928.10.1093/ajhp/zxac115CrossRefGoogle ScholarPubMed
Gauthier, TP, Menz Alvarado, LR, Collongette, EM, Knack, OC, Hauser, M. The infectious diseases pharmacist: an essential partner for health-system leadership in keeping pace with the coronavirus disease 2019 (COVID-19) pandemic. Infect Control Hosp Epidemiol 2023;44:520–521.10.1017/ice.2022.248CrossRefGoogle ScholarPubMed
Coronavirus (COVID-19) Update: FDA authorizes pharmacists to prescribe paxlovid with certain limitations. US Food and Drug Administration website. https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-pharmacists-prescribe-paxlovid-certain-limitations/. Published 2022. Accessed December 15, 2022.Google Scholar
Supplementary material: File

Wang et al. supplementary material

Figure S1 and Table S1

Download Wang et al. supplementary material(File)
File 27.5 KB